Data gathered: July 2
AI Stock Analysis - Ocugen (OCGN)
Analysis generated February 17, 2025. Powered by Chat GPT.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved eye diseases. The company's core strength lies in its pipeline, featuring both gene therapies and biological products aimed at addressing a range of ophthalmic conditions. Ocugen's most notable endeavor is its partnership with Bharat Biotech to develop a COVID-19 vaccine for the North American market.
Stock Alerts - Ocugen (OCGN)
 |
Ocugen | June 30 Employee Rating is down by 3.5% over the last month. |
|
Ocugen | June 24 Price is up by 9.6% in the last 24h. |
|
Ocugen | June 23 Price is down by -7.1% in the last 24h. |
|
Ocugen | June 20 Price is down by -7.3% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Ocugen
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 56 | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| Patents | 4 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 748 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 154,091 | Sign up | Sign up | Sign up |
| Twitter Followers | 53,751 | Sign up | Sign up | Sign up |
| Twitter Mentions | 175 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $10,000 | Sign up | Sign up | Sign up |
| Business Outlook | 39 | Sign up | Sign up | Sign up |
| Linkedin Employees | 94 | Sign up | Sign up | Sign up |
About Ocugen
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”.
| Price | $0.93 |
| Target Price | Sign up |
| Volume | 3,460,000 |
| Market Cap | $297M |
| Year Range | $0.52 - $1.2 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
HC Wainwright Reiterates Buy Rating for Ocugen (NASDAQ:OCGN)June 25 - ETF Daily News |
|
Ocugen (NASDAQ:OCGN) Given Buy Rating at Chardan CapitalJune 25 - ETF Daily News |
 |
Ocugen: Three Potential Gene-Therapy Filings By 2028June 18 - SeekingAlpha |
|
NorthCrest Asset Manangement LLC Lowers Position in Ocugen, Inc. (NASDAQ:OCGN)June 17 - ETF Daily News |
 |
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatmentJune 16 - Yahoo |
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt DiseaseJune 16 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 1.5M | 0 | 1.5M | -15M | -14M | -0.050 |
| Q4 '24 | 760,000 | 600,000 | 760,000 | -14M | -13M | -0.050 |
| Q3 '24 | 1.1M | 0 | 1.1M | -13M | -13M | -0.050 |
| Q2 '24 | 1.1M | 8.9M | 1.1M | -15M | -15M | -0.040 |
| Q1 '24 | 1M | 180,000 | 840,000 | -12M | -12M | -0.050 |
Insider Transactions View All
| Fernandes Prabhavathi filed to buy 10,000 shares at $0.9. December 2 '24 |
| Castillo Kirsten filed to buy 75,000 shares at $0.9. November 26 '24 |
| Zhang Junge filed to buy 1,077,182 shares at $0.5. June 16 '23 |
| Musunuri Shankar filed to sell 2,190,073 shares at $1.1. February 17 '23 |
| Musunuri Shankar filed to sell 2,227,950 shares at $1.3. January 19 '23 |
Similar companies
Read more about Ocugen (OCGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Ocugen?
The Market Cap of Ocugen is $297M.
What is the current stock price of Ocugen?
Currently, the price of one share of Ocugen stock is $0.93.
How can I analyze the OCGN stock price chart for investment decisions?
The OCGN stock price chart above provides a comprehensive visual representation of Ocugen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ocugen shares. Our platform offers an up-to-date OCGN stock price chart, along with technical data analysis and alternative data insights.
Does OCGN offer dividends to its shareholders?
As of our latest update, Ocugen (OCGN) does not offer dividends to its shareholders. Investors interested in Ocugen should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Ocugen?
Some of the similar stocks of Ocugen are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.